Biotech News
Related news
CRBUCaribou2026-06-29 12:00 EST
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
LYELLyell Immunopharma2026-06-25 12:00 EST
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
CRSPCRISPR Therapeutics2026-05-28 12:00 EST
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
COGTCogent Biosciences2026-06-12 12:01 EST
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
CRBUCaribou2026-06-11 12:00 EST
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
GERNGeron2026-06-01 12:00 EST
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
SANASana Biotechnology2026-07-01 13:00 EST
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
REPLReplimune Group2026-05-31 12:00 EST
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
RVMDRevolution Medicines2026-06-24 23:31 EST
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
LYELLyell Immunopharma2026-06-01 12:00 EST
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
Caribou
Allogeneic Cell Therapy Caribou Biosciences develops off-the-shelf CAR-T cell therapies using its CRISPR genome-editing platform. Its candidates incorporate multiple edits intended to improve persistence, antitumor activity and compatibility with donor-derived cells. Vispa-cel Vispacabtagene regedleucel, or vispa-cel, is an allogeneic...
Recent company news
CRBUCaribou2026-06-29 12:00 EST
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
CRBUCaribou2026-06-11 12:01 EST
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
CRBUCaribou2026-06-11 12:00 EST
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
CRBUCaribou2026-05-27 20:05 EST
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
CRBUCaribou2026-05-13 20:05 EST
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
Stock data
- Close
- 1.64 USD
- Market cap
- 230.1M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States